Fosun Pharmaceutical has announced that its subsidiary, Fosun Wanbang, has received approval from the National Medical Products Administration to conduct clinical trials for DM1001, a treatment for idiopathic Parkinson's disease in adults. The Phase I clinical trial is planned to commence in China once conditions are met. Separately, China has placed 14 EU entities, including Lafayette Group, on an export control list, prohibiting the transfer of dual-use items to them to safeguard national security and international obligations. AI
RANK_REASON This item reports on a subsidiary receiving approval for clinical trials of a drug, which falls under product development but is not a frontier release from a major AI lab.
- DM1001
- Fosun Pharmaceutical
- Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd.
- Lafayette Group
- Ministry Of Commerce
- National Medical Products Administration
- Opus 4.8
- Parkinson's disease
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
